In MOLT-4 leukemia cells, 40 µM artemisinin for 48 h had a modest effect on ATP-based viability. Co-treatment with the heme precursor ALA enhanced the effect, while the heme-synthesis inhibitor succinyl acetone prevented this enhancement. The findings are specific to this cellular design. [1]
In HT-22 cells, 25 µM artemisinin given for 12 h before a 12 h glutamate insult reduced loss of viability. Pretreatment shorter than 12 h did not protect cells. In the separate basal-exposure comparison, 6.25–50 µM did not cause detectable cytotoxicity, whereas 100 µM reduced viability after 24 h. [2]
Cell-free interaction with reduced heme
Biochemical assay · Reduced heme in a cell-free absorption assay [1]
Artemisinin changed the absorption spectrum of reduced heme. This is evidence of chemical interaction, not a binding-affinity measurement or proof of a unique intracellular target.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 µM heme; artemisinin:heme molar-ratio series. Figure 4 labels ART:heme ratios of 0.8:1, 1.6:1 and 3.2:1.
- Method
- Cell-free absorbance measurement under dithionite-reducing conditions.
- Vehicle
- DMSO-containing phosphate buffer.
- Reported limits
- Reaction duration and replicate count for Figures 4–5 are not specified in the selected text. No IC50 or affinity constant was established.
Methods and source locations
Compound reported in the paper: Artemisinin; Compound label in the paper: ART
Published material and model only; no product-batch validation or clinical inference.
Methods: Chemicals and Heme Interaction Assay; Results: Spectrophotometric characterization and Sensitivity and specificity; Figures 4–5
Heme absorption spectrum after addition of artemisinin: Absorption spectroscopy with hemin reduced by dithionite; heme-only and hemin spectra shown in Figure 4. — Results: Spectrophotometric characterization of the Heme-Artemisinin interaction; Figure 4
Decrease in heme Soret absorbance: Absorption assay; Figure 5 compares ART, DHA, artesunate and amodiaquine. — Results: Sensitivity and specificity of the heme-artemisinin interaction; Figure 5
Heme-pathway modulation of artemisinin effects in MOLT-4 cells
Cell-based study · Human MOLT-4 lymphoblastoid leukemia cells [1]
Parent artemisinin had a modest effect on the ATP-based viability readout. Aminolevulinic acid enhanced the effect, and succinyl acetone prevented this enhancement.
Literature-Reported Treatment Conditions
- Treatment concentration
- 40 µM artemisinin
- Exposure duration
- 48 h
- Method
- Cell exposure followed by ATP measurement.
- Vehicle
- DMSO; equal-volume DMSO controls.
- Co-treatment
- Separate artemisinin-alone, artemisinin + 1 mM ALA, and artemisinin + 1 mM ALA + 0.5 mM SA conditions.
- Reported limits
- Final DMSO percentage and exact replicate count for Figure 8 are not stated in the selected material. No IC50 is reported for this design.
Methods and source locations
Compound reported in the paper: Artemisinin; Compound label in the paper: ART
Published material and model only; no product-batch validation or clinical inference.
Methods: Chemicals, Cell Culture and cytotoxicity assays, Statistical analysis; Results: HI HTS compound cytotoxicity and dependence upon heme synthesis; Figure 8
Cellular ATP response to artemisinin and heme-pathway modifiers: CellTiter-Glo ATP assay; matched DMSO, ALA and ALA/SA controls. — Results: HI HTS compound cytotoxicity and dependence upon heme synthesis, parent-artemisinin paragraphs; Figure 8
Exposure timing and protection from glutamate injury in HT-22 cells
Cell-based study · Mouse HT-22 hippocampal cell line [2]
Artemisinin pretreatment protected HT-22 cells from glutamate-associated loss of viability under the tested conditions. Protection depended on pretreatment duration, and 100 µM artemisinin alone reduced viability.
Literature-Reported Treatment Conditions
- Treatment concentration
- 6.25, 12.5, 25, 50 or 100 µM artemisinin in the basal viability series; 25 µM in the pretreatment-time comparison.
- Exposure duration
- Basal exposure: 24 h. Protective condition: 12 h pretreatment followed by 12 h glutamate insult. Timing comparison includes 0, 1, 3, 6, 12 and 24 h pretreatment.
- Method
- Cell pretreatment and viability assay.
- Co-treatment
- Injury conditions used 6 mM glutamate; separate artemisinin-only and untreated controls.
- Reported limits
- Artemisinin solvent and final vehicle concentration are not reported in the selected procedures. Experiments were at least in triplicate; exact n per panel is unspecified. Whether artemisinin was removed before glutamate was not established.
Methods and source locations
Compound reported in the paper: Artemisinin; Compound label in the paper: ART
Published material and model only; no product-batch validation or clinical inference.
Experimental Procedures: Cell Culture, Cell Viability Assay, Statistical Analysis; Results: Artemisinin Pretreatment Reduced Glutamate-Induced Cytotoxicity in HT-22 Cells; Figure 1A–D
Viability after glutamate injury: Calcein-AM assay, normalized to control; Figure 1B–C identifies 6 mM glutamate. — Results first subsection; Figure 1B–C; Cell Viability Assay
Viability after artemisinin alone: Calcein-AM assay normalized to untreated control. — Results first subsection; Figure 1A